ARYL SULPHATASE A (METACHROMATIC LEUCODYSTROPHY)

The Aryl Sulphatase A test measures the activity of arylsulfatase A, also called ARSA, an enzyme that works inside cellular structures known as lysosomes. This enzyme helps break down sulfatides, which are fatty substances found particularly in the protective myelin covering of nerves. When ARSA activity is severely deficient, sulfatides can accumulate in the brain, spinal cord, peripheral nerves and certain other organs.

A marked deficiency of ARSA activity is associated with metachromatic leukodystrophy, commonly abbreviated as MLD. MLD is a rare inherited lysosomal storage disorder that progressively damages myelin. Myelin allows electrical signals to travel efficiently through the nervous system. Its deterioration can cause changes in movement, muscle control, sensation, behaviour, learning and other neurological functions.

Benefits of the Test

• Measures arylsulfatase A enzyme activity.
• Supports the evaluation of suspected metachromatic leukodystrophy.
• Helps investigate progressive neurological or developmental symptoms.
• May help distinguish MLD from other leukodystrophies and neurological disorders.
• Provides important information before confirmatory genetic testing.
• May support family screening when a disease-causing ARSA variant is known.

Why Doctors Recommend This Test

A neurologist, paediatrician, geneticist or metabolic specialist may recommend this test when symptoms or imaging findings suggest a disorder affecting myelin. In infants or young children, possible signs include delayed development, loss of previously acquired abilities, difficulty walking, muscle weakness, abnormal muscle tone, swallowing problems, seizures or changes in vision and hearing.

Juvenile-onset MLD may initially present with reduced school performance, behavioural changes, difficulty concentrating, declining coordination or progressive walking problems. Adult-onset disease can sometimes begin with psychiatric, behavioural or cognitive symptoms before clear movement difficulties develop. These symptoms are not specific to MLD and can occur in several other neurological conditions.

The test may also be requested when brain magnetic resonance imaging shows white-matter abnormalities consistent with a leukodystrophy. Enzyme analysis is one part of the diagnostic process. A low result usually requires confirmation using ARSA gene testing and, in selected situations, measurement of urinary sulfatides or additional biochemical investigations.

Preparation Before Test

The required specimen depends on the laboratory method and may include blood collected for leukocyte enzyme analysis or another specimen specifically requested by the testing laboratory. Follow the collection instructions provided by the treating doctor and Focus Diagnostics. Fasting is generally not required unless additional fasting investigations are ordered.

Inform the healthcare team about recent blood transfusions, stem-cell transplantation, bone-marrow transplantation, serious illness and all current medicines. These factors may influence specimen selection or interpretation. Do not stop prescribed medication without medical advice.

Enzyme testing requires careful specimen collection, storage and transport. Samples should be submitted in the correct tube and maintained under the conditions specified by the performing laboratory. Improper handling can reduce enzyme activity and potentially produce a misleading result.

Normal Reporting Time

Aryl Sulphatase A measurement is a specialized enzyme investigation and is generally reported within several working days. Turnaround time may vary because testing may be performed in scheduled batches or referred to a specialist biochemical genetics laboratory. Focus Diagnostics will confirm the applicable reporting schedule during sample collection.

Who Should Take This Test?

This test may be appropriate for children or adults with unexplained progressive neurological decline, loss of developmental milestones, abnormal muscle tone, peripheral neuropathy or brain-imaging findings suggestive of a leukodystrophy. It may also be considered for biological relatives of a person with confirmed MLD under genetic counselling guidance.

The test is not intended as routine population screening. Because MLD is inherited in an autosomal recessive pattern, family members may require targeted genetic testing rather than enzyme testing alone. A genetic counsellor can explain carrier status, reproductive implications and the most appropriate testing strategy.

Detailed Information

Metachromatic leukodystrophy most commonly results from disease-causing variants in the ARSA gene. A person usually develops the condition after inheriting an affected gene copy from each parent. Parents who carry one altered copy generally do not develop MLD. The age of onset and speed of progression can vary considerably between affected individuals.

Very low ARSA activity can support suspected MLD, but enzyme results require careful interpretation. Some people have arylsulfatase A pseudodeficiency, in which laboratory enzyme activity appears low without the sulfatide accumulation and progressive neurological disease characteristic of MLD. For this reason, low enzyme activity alone should not be treated as definitive proof of the disease.

Confirmation commonly involves ARSA molecular genetic testing and may include urinary sulfatide analysis. Rarely, MLD-like disease may involve a different protein required for sulfatide breakdown, such as saposin B, meaning ARSA enzyme activity may not show the expected deficiency. Clinical findings, neurological examination, MRI, nerve-conduction studies and other metabolic tests can provide additional evidence.

A result within the laboratory reference interval makes classic ARSA deficiency less likely but does not explain the patient's symptoms or exclude every related disorder. Results must be reviewed by a specialist familiar with inherited metabolic and neurological diseases. Early specialist evaluation is important because treatment suitability and clinical management can depend on disease stage, subtype and individual circumstances.